Num­ber 7? Cel­gene part­ner BeiGene joins the crowd with stel­lar PD-1/L1 da­ta from a piv­otal test

Get ready for the sec­ond wave of PD-1/L1 check­point in­hibitors.

BeiGene $BGNE an­nounced just ahead of the start of the week in Bei­jing that their PD-1 tislelizum­ab — part­nered with Cel­gene $CELG — scored stel­lar da­ta in a small Phase II tri­al for clas­si­cal Hodgkin’s lym­phoma among pa­tients who had ei­ther failed or couldn’t take au­tol­o­gous stem cell trans­plan­ta­tion. This is their first piv­otal tri­al, and it un­der­scores why Cel­gene inked a $1.4 bil­lion deal to buy in­to the drug — which may end up as the 7th new check­point to hit the glob­al mar­ket.

Jane Huang

This is a very fa­mil­iar are­na for the check­point field. Bris­tol-My­ers Squibb’s Op­di­vo gained an ac­cel­er­at­ed ap­proval back in 2016 for cHL — with a 7% rate of CRs — and Mer­ck was close be­hind with an OK a year ago as a 4th line ther­a­py fol­low­ing promis­ing re­sults for Keytru­da.

BeiGene, though, would be first in Chi­na, with a sol­id show­ing un­der­scor­ing their drug’s po­ten­tial.

In this new case their drug hit an ob­jec­tive re­sponse rate of 73%, with a 50% CR, and the me­di­an du­ra­tion of re­sponse — over a 6-month av­er­age fol­low-up — had not been reached. 

The transpa­cif­ic BeiGene plans to hus­tle up an ap­pli­ca­tion in Chi­na while they work with Cel­gene on a late-stage pro­gram that in­cludes tri­als for “non-small cell lung can­cer, he­pa­to­cel­lu­lar car­ci­no­ma, and esophageal squa­mous cell car­ci­no­ma; as well as two glob­al Phase 2 tri­als in pa­tients with pre­vi­ous­ly treat­ed he­pa­to­cel­lu­lar car­ci­no­ma or with R/R ma­ture T-and NK-cell lym­phomas, and an ad­di­tion­al piv­otal Phase 2 tri­al in Chi­na in urothe­lial can­cer.”

That’s not all.

BeiGene al­so an­nounced that af­ter dis­cus­sions with the FDA they’re prep­ping an NDA for the first half of 2019 with plans to pur­sue an ac­cel­er­at­ed ap­proval of their drug zanubru­ti­nib for pa­tients with Walden­ström macroglob­u­line­mia based on their glob­al Phase I study. “A fi­nal de­ter­mi­na­tion to sub­mit the NDA will be made sub­se­quent to the pre-NDA meet­ing with FDA af­ter ob­tain­ing ma­ture da­ta from the study this fall.”

Right now there are 5 PD-1/L1 check­points on the mar­ket. Re­gen­eron $REGN and Sanofi $SNY plan to make that 6. And BeiGene looks well po­si­tioned to hit the 7th spot. As of now, there are still hun­dreds of on­go­ing tri­als, in­clud­ing a mob of com­bo stud­ies, as Mer­ck dukes it out with Bris­tol-My­ers for the top po­si­tion of a grow­ing mega­mar­ket. As of now, Mer­ck looks set to take the lead with a string of suc­cess­es in front­line lung can­cer.

Many of these new check­points are be­ing stud­ied in Chi­na, where a group of deep-pock­et in­vestors have been birthing new bio­phar­ma com­pa­nies look­ing to fill the gap of drug tech that sep­a­rates the boom­ing Asian mar­ket with the West.

But there are al­so more than 150 of these ex­per­i­men­tal PD-1/L1 drugs in the glob­al pipeline, ac­cord­ing to re­search from the Can­cer Re­search In­sti­tute, and even­tu­al­ly the world will ei­ther run out of un­chart­ed on­col­o­gy ter­rain, mar­ket po­ten­tial or pa­tients look­ing to en­roll in a tri­al. Then the new ar­rivals will ei­ther shriv­el or the whole mar­ket will be swift­ly com­modi­tized with mul­ti­ple play­ers.

That line, though, has not yet been reached.

“We are ex­cit­ed to an­nounce the pre­lim­i­nary topline re­sults from our first piv­otal tri­al for tislelizum­ab. De­spite short fol­low-up, we be­lieve there was a demon­stra­tion of ro­bust ac­tiv­i­ty, with high over­all and com­plete re­sponse rates in ad­di­tion to a safe­ty pro­file that is con­sis­tent with oth­er PD-1 in­hibitors. We be­lieve these strong re­sults will sup­port our first reg­u­la­to­ry fil­ing in Chi­na for tislelizum­ab, which is planned for lat­er this year,” com­ment­ed Jane Huang, chief med­ical of­fi­cer, hema­tol­ogy, at BeiGene.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Once again Bischofberger and his old boss, former Gilead chief John Martin, added their own money to the new $105 million raise aimed at building up their R&D engine and the team who’s doing the drug discovery work — on both coasts. Also coming back is Arie Belldegrun, the biotech builder who sold Kite to Gilead for $12 billion, and now plays the role of global wheeler dealer who’s taking a shot at cracking the off-the-shelf CAR-T challenge at Allogene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

Part club, part guide, part land­lord: Arie Bellde­grun is blue­print­ing a string of be­spoke biotech com­plex­es in glob­al boom­towns — start­ing with Boston

The biotech industry is getting a landlord, unlike anything it’s ever known before.

Inspired by his recent experiences scrounging for space in Boston and the Bay Area, master biotech builder, investor, and global dealmaker Arie Belldegrun has organized a new venture to build a new, 250,000 square foot biopharma building in Boston’s Seaport district — home to Vertex and a number of up-and-coming biotech players.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

An increase in demand of up to 79% for clinical trials in China has prompted Novotech the Asia-Pacific CRO to rapidly expand the China team, appointing expert local clinical executives to their Shanghai and Hong Kong offices. The company is planning to expand their team by 30% over the next quarter.

Novotech China has seen considerable demand recently which is borne out by research from GlobalData:
A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world, with growth as high as 79% in China.
Novotech CEO Dr John Moller said China offers the largest population in the world, rapid economic growth, and an increasing willingness by government to invest in research and development.
Novotech’s 23 years of experience working in the region means we are the ideal CRO partner for USA biotechs wanting to tap the research expertise and opportunities that China offers.
There are over 22,000 active investigators in Greater China, with about 5,000 investigators with experience on at least 3 studies (source GlobalData).

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

For years the big trend among dealmakers at the major players has been centered on ratcheting down upfront payments in favor of bigger milestones. Better known as biobucks for some. But with the top 15 companies competing for the kind of “transformative” pacts that can whip up some excitement on Wall Street, with some big biotechs like Regeneron now weighing in as well, cash is king at the high stakes table.

We asked Chris Dokomajilar, the head of DealForma, to crunch the numbers for us, looking over the top 20 deals for the past decade and breaking it all down into the top alliances already created in 2019. Gilead has clearly tipped the scales in terms of the coin of the bio-realm, with its record-setting $5 billion upfront to tie up to Galapagos’ entire pipeline.

Dokomajilar notes:

We’re going to need a ‘three comma club’ for the deals with over $1 billion in total upfront cash and equity. The $100 million-plus club is getting crowded at 164 deals in the last decade with new deals being added towards the top of the chart. 2019 already has 14 deals with at least $100 million in upfront cash and equity for a total year-to-date of over $9 billion. That beats last year’s $8 billion and sets a record.

Add upfronts and equity payments and you get $11.5 billion for the year, just shy of last year’s record-setting $11.8 billion.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

UP­DAT­ED: With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

Merck — one of the last large biopharmaceuticals companies in the beleaguered field of antibiotic drug development — on Wednesday said the FDA had sanctioned the approval of its combination antibacterial for the treatment of complicated urinary tract and intra-abdominal infections.

To curb the rise of drug-resistant bacteria and maintain the efficacy of the therapy, Recarbrio (and other antibacterials) — the drug must be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible gram-negative bacteria, Merck $MRK said.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

John McHutchison in 2012. Getty Images

The $1.1M good­bye: Gilead CSO John McHutchi­son is out as Daniel O’Day shakes up the se­nior team

Just a little more than a year after John McHutchison grabbed a promotion to become CSO at Gilead in the wake of Norbert Bischofberger’s exit, he’s out amid a shakeup of the senior team that is also triggering the departure of two other top execs.

Gilead stated that McHutchison “has decided to step down” from the job as of August 2nd. And their SEC filing notes that he’ll be getting a $1.1 million check to settle up on his contract.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.

Thomas Gajewski, David Steinberg. (CRI, Pyxis)

Bay­er, Long­wood back star re­searcher's deep dive in­to the tu­mor mi­croen­vi­ron­ment for new I/O tar­gets

From PD-1 targeting to the RAS pathway to the STING complex, Thomas Gajewski has spent the past two decades of his career decoding the various ways the immune system can be unleashed to defend against cancer. So when the University of Chicago professor comes around to putting all his findings into a new platform for finding new targets, VCs and pharma groups alike pay attention.

“He’s been studying T cells for 20 years, plus he’s one of the world’s leaders if not the world leader in the space,” David Steinberg, partner at Longwood Fund, said. “Furthermore, let me add he did a lot of the foundational research and also some of the seminal clinical trials in the existing set of I/O agents. He understands the space really well, he understands the current strengths, and I think he understood really well what was missing, so he knew where to look.”

Kamala Harris speaking yesterday at the Des Moines Register Iowa Presidential Candidate Forum [via Getty]

Who’s the tough­est on drug prices? A game of po­lit­i­cal one-up­man­ship is dri­ving the pol­i­cy de­bate in Wash­ing­ton

Earlier this week we got a look at Senator Kamala Harris’ position on drug prices. She’s proposing that HHS take an average price from single-payer systems like the UK, Germany and Canada — which leverage market access for lower prices — and use that to set the US price. Anything drug companies collect above that would be taxed at a rate of 100%.

And the rhetoric is scathing:
While families struggle to make it to the end of the month, pharmaceutical companies are turning record profits. They’re spending nearly as much on advertising as R&D. They’re manipulating their market power to hike prices on lifesaving generic drugs. They’re making twice the profit of the average industry in America and still increased drug prices by 10.5% over the past six months alone. Meanwhile, they are charging dramatically higher prices to American consumers.
That’s an escalation on Joe Biden’s plan, which includes drug importation from those cheaper markets as well as allowing Medicare to negotiate prices — something that virtually all Dems agree on now.

SJ Lee [File photo]

Go­ing in­side cells, Sung Joo Lee has sketched some big goals for his small — but glob­al — team of drug hunters

For a small biotech based in South Korea with a research arm in Cambridge, MA, Orum Therapeutics has sketched out some big goals aimed at developing antibodies for intracellular targets. And now they have a new $30 million round to push the work forward, aiming at a slate of currently undruggable quests.

Orum has been working on a platform tech out of Ajou University that relies on endocytosis to smuggle antibodies and their cargo inside a cell. They’ve published work in Nature that illustrates its preclinical potential in RAS mutations, and KRAS is on their list of targets. 

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,900+ biopharma pros reading Endpoints daily — and it's free.